Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsors and Collaborators: |
Ophthalmic Consultants of Boston Allergan |
---|---|
Information provided by: | Ophthalmic Consultants of Boston |
ClinicalTrials.gov Identifier: | NCT00347828 |
The purpose of this study is to analyze the effect of Zymar and Vigamox on ocular surface bacteria. We believe that Zymar will eradicate more ocular surface bacteria than Vigamox.
Condition | Intervention | Phase |
---|---|---|
Eye Infection Infection |
Drug: Moxifloxacin ophthalmic solution 0.5% Drug: Gatifloxacin ophthalmic solution 0.3% |
Phase IV |
Study Type: | Interventional |
Study Design: | Prevention, Randomized, Double-Blind, Historical Control, Single Group Assignment, Efficacy Study |
Official Title: | Prospective Study Comparing the Effectiveness of Zymar and Vigamox for Preoperative Antibiotic Sterilization of the Ocular Surface After Loading Dose |
Estimated Enrollment: | 40 |
Study Start Date: | June 2006 |
Estimated Study Completion Date: | June 2006 |
Topical antibiotics are frequently used before surgical procedures with the intent of targetting and reducing the number of bacteria on the surface of the eye. These bacteria serve as potential sources for post-operative infection. One commonly used method is the administration of antibiotic drops 3 times: 1 hour prior to surgery at intervals of 5 minutes. Studies in the lab have shown that the preservative benzalkonium chloride 0.005%, part of the Zymar antibiotic drop preparation, allows the antibiotic to act more effectively than the antibiotic Vigamox, which does not include this preservative.
Comparison: The effect of Zymar antibiotic eye drops on conjunctival cultures compared to the effect of Vigamox on conjunctival cultures as measured by conjunctival cultures taken prior to treatment and then one hour after administration of eye drops 3 times, at 5 minute intervals.
Ages Eligible for Study: | 25 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
Exclusion Criteria:
United States, Massachusetts | |
Ophthalmic Consultants of Boston | |
Boston, Massachusetts, United States, 02114 |
Principal Investigator: | Michael B Raizman, B.A./M.D. | Ophthalmic Consultants of Boston |
Study Director: | Sandra Y Cho, B.A./M.D. | New England Eye Center/Tufts-New England Medical Center |
Study Director: | Rahul Mandiga, B.S. | New England Eye Center/Tufts-New England Medical Center |
Study ID Numbers: | Allergan/Z101 |
Study First Received: | June 30, 2006 |
Last Updated: | July 3, 2006 |
ClinicalTrials.gov Identifier: | NCT00347828 |
Health Authority: | United States: Institutional Review Board |
Antibiotic prophylaxis Vigamox Moxifloxacin Zymar |
Gatifloxacin Preoperative antibiotic Eye infection |
Fluoroquinolones Moxifloxacin Eye Diseases Eye Infections Gatifloxacin |
Anti-Bacterial Agents Anti-Infective Agents Communicable Diseases Molecular Mechanisms of Pharmacological Action Therapeutic Uses |
Enzyme Inhibitors Infection Nucleic Acid Synthesis Inhibitors Pharmacologic Actions |